anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, phthisiobacteriology. SUBSTANCE: invention proposes the developed nutrient medium for mycobacterium tuberculosis used for assay of their medicinal resistance based on the modified synthetic Soton's medium that comprises additionally 0.35% of nutrient agar and 25% of equine serum. Using this medium provides obtaining the visual growth of mycobacterium tuberculosis by 2.1-2.8-fold more rapidly (on 3-5 days) as compared on the known medium. The proposed medium can be used in practice of phthisiobacteriological laboratories for the accelerated obtaining data about the medicinal resistance of clinical strains to isoniazid, streptomycin and rifampicin. EFFECT: improved assay method, valuable properties of medium. 2 tbl
BACKGROUND: Drains are used to reduce abdominal collections after procedures where such risk exists. Using abdominal drains after cholecystectomy has been controversial since the open surgery era. Universally accepted indications and agreement exist that routine drainage is unnecessary but the role of selective drainage remains undetermined. This study evaluates the indications and benefits of sub-hepatic drainage in patients undergoing laparoscopic cholecystectomy (LC) and bile duct exploration (BDE) in a specialist unit with a large biliary emergency workload.
METHODS: Prospectively collected data from 6,140 LCs with a 46.6% emergency workload over 30 years was reviewed. Demographic factors, pre-operative presentations, imaging and operative details in patients with and without drains were compared. Sub-hepatic drains were inserted after all transductal explorations, subtotal cholecystectomies, almost all open conversions and 94% of LC for empyemas. Adverse or beneficial postoperative drain-related outcomes were analysed.
RESULTS: Abdominal drains were utilised in 3225/6140 (52.5%). Patients were significantly older with more males. 59.4% were emergency admissions. Preoperative imaging showed thick-walled gallbladders in 25.2% and bile duct stones or dilatation in 36.2%. At operation they had cystic duct stones in 19.8%, acute cholecystitis, empyema or mucocele in 28.4% and operative difficulty grades III or higher in 59%. 38% underwent BDE, 5.4% had fundus-first dissection and the operating times were longer ( 80 vs.45 min). Drain related complications were rare; 3 abdominal pains after anaesthetic recovery settling when drains were removed, 2 drain site infections and one re-laparoscopy to retrieve a retracted drain. 55.8% of 43 bile leaks and 35% of 20 other collections in patients with drains resolved spontaneously.
CONCLUSIONS: The utilisation of drains in this study was relatively high due to the high emergency workload and interest in BDE. While drains allowed early detection of bile leakage, avoiding some complications and monitoring conservative management to allow early reinterventions, the study has identified operative criteria that could potentially limit drain insertion through a selective policy.
The most severe form of COVID-19 treated in intensive care for acute respiratory failure may have a poor prognosis. Both the level of IL-6 and the severity of the lymphopenia have been associated to the poor prognosis. Better knowledge of the time evolution of the circulating immune cells subpopulations and functions will help to best tailor the treatment: anti-inflammatory strategy at the initial phase might be rapidly shifted to immune stimulation when immunodepression is diagnosed.

It is then essential to assess the patients' immune status using flowcytometry methods to characterize both innate and adaptive immunity of the whole blood circulating immune peripheral blood mononuclear cells (PBMC). After cell staining with the adequate cell markers, the flowcytometry (NAVIOS® Flow Cytometer (Beckman Coulter) allowed to analyze the number and the function of the cells with an adequate gating strategy and the Kaluza® software v2.1 (Beckman Coulter). The data were then grouped by time intervals referring to the onset of symptoms and also to the ICU admission. The trend for innate immunity (monocytes number and subpopulations, HLA-DR expression) and for adaptive immunity (lymphocytes and subpopulations) will be analyzed. Since it is unknown if whole blood CD3/CD4 and CD3/CD8 lymphocytes elicit an "exhaustion" pattern and/or an abnormal response, an ex vivo testing of their reactivity for SARS-CoV-2 viral proteins will be performed. This test of polyfunctionality will characterize the intracellular cytokine expression (IL-1 beta, TNFalpha, and INFgamma) both for CD4 and CD8 T cells.
This invention discloses composition and manufacturing process(es) of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants  Crinum asiaticum  and  Crocus sativus . This drug was administered to human volunteers by oral and intranasal routes in effective amount for effective time period. Effective amount and effective time of administration varies from one human volunteer to another depending upon age, body weight, length of disease, severity of disease, type of the disease.  In vitro  experiments show that this botanical drug causes proliferation and differentiation of stem cells. Details of these in vitro experiments will be given in next patent.
In healthy subjects, the oral bioavailability of sotalol is 90 to 100%. After oral administration, peak plasma concentrations are reached in 2.5 to 4 hours, and steady-state plasma concentrations are attained within 2 to 3 days (i.e., after 5 to 6 doses when administered twice daily). Over the dosage range 160 to 640 mg/day sotalol displays dose proportionality with respect to plasma concentrations. Distribution occurs to a central (plasma) and to a peripheral compartment, with a mean elimination half-life of 12 hours. Dosing every 12 hours results in trough plasma concentrations which are approximately one-half of those at peak.

Sotalol does not bind to plasma proteins and is not metabolized. Sotalol shows very little intersubject variability in plasma levels. The pharmacokinetics of the d and l enantiomers of sotalol are essentially identical. Sotalol crosses the blood brain barrier poorly. Excretion is predominantly via the kidney in the unchanged form, and therefore lower doses are necessary in conditions of renal impairment (see DOSAGE AND ADMINISTRATION). Age per se does not significantly alter the pharmacokinetics of sotalol, but impaired renal function in geriatric patients can increase the terminal elimination half-life, resulting in increased drug accumulation. The absorption of sotalol was reduced by approximately 20% compared to fasting when it was administered with a standard meal. Since sotalol is not subject to first-pass metabolism, patients with hepatic impairment show no alteration in clearance of sotalol.

The combined analysis of two unblinded, multicenter trials (a single dose and a multiple dose study) with 59 children, aged between 3 days and 12 years, showed the pharmacokinetics of sotalol to be first order. A daily dose of 30 mg/m2 of sotalol was administered in the single dose study and daily doses of 30, 90 and 210 mg/m2 were administered q8h in the multi-dose study. After rapid absorption with peak levels occurring on average between 2 to 3 hours following administration, sotalol was eliminated with a mean half-life of 9.5 hours. Steady-state was reached after 1 to 2 days. The average peak to trough concentration ratio was 2. BSA was the most important covariate and more relevant than age for the pharmacokinetics of sotalol. The smallest children (BSA <0.33m2) exhibited a greater drug exposure (+59%) than the larger children who showed a uniform drug concentration profile. The intersubject variation for oral clearance was 22%.
Aluminum phosphide (ALP) is a well-known fumigant known also as rice pill or wheat pill. It is considered an ideal pesticide since it is effective to preserve stored grains against insects and rodents without leaving residues, in addition to its availability and low cost. In Egypt, it has become a common method of suicide over the last few years because it is cheap and easily accessible. Cardiomyocytes are one of the main targets for ALP. ALP-induced cardiotoxicity involves detrimental effects such as direct myocardial tissue damage, hypoperfusion, myocarditis, pericarditis, and arrhythmias leading to circulatory failure. Levosimendan, an inotropic agent, enhances cardiac contractility through calcium sensitization with minimal oxygen demand and, in turn, decreases the risk of arrhythmia. However, limited studies have investigated the role of levosimendan in the treatment of ALP induced cardiotoxicity.
The intervention group received four weekly training sessions of health literacy education. Each educational session lasted an average of 50 minutes. The students were divided into four groups with an average of 25 students in each group.
PROBLEM TO BE SOLVED: To obtain a medicine preparation having an action capable of continuously increasing a level of the antihemophilic 8th factor in vivo by using a biologically active specific styptic factor and/or its fraction as an effective ingredient. SOLUTION: In this medicine preparation, von Willebrand's factor(vWF) and/or a vWF fraction having a prolonged biological half time is used. The vWF and/or the vWF fraction is preferably one having >=20 hours half time in vivo and a multimer structure consisting of singlets. The vWF fraction preferably consists of low molecular weight vWFs having <5 million dalton, especially <3 million dalton. The solution concentration at an administration is preferably 1-1000U/ml of the vWF and/or the vWF fraction. As the vWF, a recombined vWF is especially preferable. The vWF can preferably be fractionated by a chromatographic purification, especially by an ion exchange and/or an affinity chromatography.
In Group 1, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Fuji® II LC, GC Corporation, Tokyo, Japan) (test 1). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
FIELD: food industry. ^ SUBSTANCE: invention relates to food and pharmaceutical industry. Infant food composition, containing protein, fats, carbohydrates, nucleotides, nucleosides and nonprotein negatively charged polygalacturonic acid taken at in certain amounts. Application of composition for production of composition for infant feeding. Application of nutrient composition to produce composition for treatment and/or prophylactics of inflammatory disease, diarrhea, eczema and/or atopic dermatitis of a baby. ^ EFFECT: nutrient composition efficiently imitates protective action of human milk, in particular, against allergies and infections. ^ 9 cl, 4 ex
AIMS: Although physiological effects of hydrophilic- (H-) and lipophilic- (L-) antioxidant capacities (AOCs) are suggested to differ, the association of an antioxidant-rich diet and chronic kidney disease (CKD) incidence has not been examined. We therefore explored the association between the H- or L-AOC of a whole Japanese diet and CKD risk in a general population.
METHODS: A total of 922 individuals without CKD (69.2% women; mean age, 59.5 years old) from Ohasama Town, Japan, were examined. CKD incidence was defined as the presence of proteinuria and/or an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m2. Consumption of H-/L-AOC was determined based on the oxygen radical absorbance capacity in a specially developed Japanese food AOC database. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for new-onset CKD using a Cox proportional hazards model.
RESULTS: During the median follow-up of 9.7 years, 137 CKD incidents were recorded. After adjusting for potential confounding variables, the highest quartile of L-AOC was significantly associated with a 51% reduced CKD risk among only women. An increased L-AOC intake was more effective in preventing eGFR reduction than in preventing proteinuria in women. These associations were not seen for H-AOC intake in both sexes and L-AOC intake in men.
CONCLUSIONS: A high intake of lipophilic antioxidants may be associated with a reduced CKD risk. The balance between dietary antioxidant intake and pro-oxidants induced by unhealthy lifestyles may be crucial for preventing future kidney deterioration.
This study is being done to assess safety and tolerability and to explore the effectiveness of a new, experimental drug in the treatment of moderate to severe depression. Approximately 225 patients with depression will be recruited for the study. Patients who meet study criteria will need to stop taking any depression medications they are currently using. They will be randomly assigned to one of 3 treatment arms; each patient has an equal chance of receiving 20 mg JNJ-18038683, 20 mg escitalopram, or placebo. Placebo has no active drug. Escitalopram is a drug currently approved to treat depression. This is a blinded study, ie the patient, the study doctor, and the study sponsor will not know what treatment the patient receives until all patients complete the study. Patients receiving either escitalopram or JNJ-18038683 will be titrated up to their assigned dose, receiving 10 mg doses for one week prior to increasing to 20 mg. Patients who are not able to tolerate 20 mg of JNJ-18038683 will be allowed to drop down to the 10 mg dose at any time after the titration period. Patients taking 20 mg escitalopram will receive 10 mg at their final week to taper off of the drug. Patients will receive a drug blister card at each weekly visit containing drug for the upcoming week. The study doctor and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit, patients will return weekly for 9 additional study visits. After completing the study, patients may resume other depression medications. Medical and psychiatric history, physical examination, blood pressure, heart rate, temperature, weight and electrocardiograms (ECGs) will be checked periodically. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. Questionnaires relating to depression, sleep and sexual experience will be administered throughout the study. Each day for nine weeks, patients will take orally two JNJ-18038683 tablets, active and/or placebo, and two escitalopram capsules, active and/or placebo.
The invention disclosesA sialidase for resisting helicobacter pylori colonization in stomach is provided. Belongs to the technical field of genetic engineering vaccines. The amino acid sequence of the sialidase is shown in SEQ ID NO. 1; the nucleotide sequence of the coding gene is shown in SEQ ID NO.2, and a construction method and application are provided. The invention adopts gene engineering technology to clone and express the recombinant protein of the helicobacter pylori sialidase, the expression level of the supernatant is high, the separation and purification steps are simple and convenient, the immune titer is high, and the protein has protectiveness. The sialidase recombinant protein can be directly mixed with mucosal adjuvant LT (B) 5 The composition can be used in combination for oral immunization.
This is a multicenter, randomized (study drug assigned by chance), open-label (participants and researchers are aware of the treatment participants are receiving) study to evaluate the safety and efficacy of talacotuzumab or daratumumab. Approximately 60 participants (30 to receive talacotuzumab and 30 to receive daratumumab) will be enrolled and then assigned randomly on a 1:1 basis to receive either talacotuzumab or daratumumab. The study consists of: a Screening Phase of up to 28 days during which participant eligibility will be reviewed and approved by the sponsor prior to randomization, a Treatment Phase that will extend from the first dose on Cycle 1 Day 1 until study drug discontinuation, and a Post-treatment Follow up Phase beginning once the participant discontinues talacotuzumab or daratumumab. Study drugs will continue to be administered until disease progression, lack of response, unacceptable toxicity, withdrawal of consent, or study end. Safety will be monitored throughout the study. The talacotuzumab arm of the study is closed for enrollment.
Parents of subjects in the parent-administered TCM massage group (n=30) will attend 2 training sessions (5 hours in total) to learn and practice the parent-administered TCM massage for ADHD before treatment starts. The parents will be told to practice the TCM massage on their child every 2 days for 2 months.
BACKGROUND: Diagnosis can often be recorded in electronic medical records (EMRs) as free-text or using a term with a diagnosis code. Researchers, governments, and agencies, including organisations that deliver incentivised primary care quality improvement programs, frequently utilise coded data only and often ignore free-text entries. Diagnosis data are reported for population healthcare planning including resource allocation for patient care. This study sought to determine if diagnosis counts based on coded diagnosis data only, led to under-reporting of disease prevalence and if so, to what extent for six common or important chronic diseases.
METHODS: This cross-sectional data quality study used de-identified EMR data from 84 general practices in Victoria, Australia. Data represented 456,125 patients who attended one of the general practices three or more times in two years between January 2021 and December 2022. We reviewed the percentage and proportional difference between patient counts of coded diagnosis entries alone and patient counts of clinically validated free-text entries for asthma, chronic kidney disease, chronic obstructive pulmonary disease, dementia, type 1 diabetes and type 2 diabetes.
RESULTS: Undercounts were evident in all six diagnoses when using coded diagnoses alone (2.57-36.72% undercount), of these, five were statistically significant. Overall, 26.4% of all patient diagnoses had not been coded. There was high variation between practices in recording of coded diagnoses, but coding for type 2 diabetes was well captured by most practices.
CONCLUSION: In Australia clinical decision support and the reporting of aggregated patient diagnosis data to government that relies on coded diagnoses can lead to significant underreporting of diagnoses compared to counts that also incorporate clinically validated free-text diagnoses. Diagnosis underreporting can impact on population health, healthcare planning, resource allocation, and patient care. We propose the use of phenotypes derived from clinically validated text entries to enhance the accuracy of diagnosis and disease reporting. There are existing technologies and collaborations from which to build trusted mechanisms to provide greater reliability of general practice EMR data used for secondary purposes.
Use ZYCLARA, 3.75% for the treatment of EGW. Apply a thin layer of ZYCLARA cream once daily before bedtime to EGW until total clearance or for up to 8 weeks. To treat the wart area, use up to 0.25 grams (one packet or one full actuation of the pump) at each application. Leave ZYCLARA on the skin for approximately 8 hours and then remove with mild soap and water.

For local skin reactions, a dosage interruption of several days may be taken if required by the patient's discomfort or severity of the local skin reaction; resume treatment once the reaction subsides [see Warnings and Precautions (5.1)] . 

Non-occlusive dressings such as cotton gauze or cotton underwear may be used in the management of skin reactions.

Inform uncircumcised patients treating warts under the foreskin to retract the foreskin and clean the area daily.

ZYCLARA may weaken condoms and vaginal diaphragms, therefore, concurrent use is not recommended.
A system for selection of a medical provider (MP) by a requesting patient based on preferences for the MP includes a first model modeling the preferences of a plurality of patients for select MPs and trained on a first training data set. A second model is provided for modeling the preferences of a plurality of MPs for select patients and trained on a second training data set. A controller controls the first and second models to select at least a portion of available MPs in an available MP data set for input of the associated representative information to the first and second model MP inputs. A patient rank calculator accumulates the output patient determined preferences for MPs associated with the selected at least a portion of the available MPs and generates a MP ranking for each of the selected at least a portion of the available MPs. An MP rank calculator accumulates the output MP determined preferences for the requesting patient for each of the selected at least a portion of the available MPs and generates a patient ranking for each of the selected at least a portion of the available MPs. A plurality of weighting blocks are associated with at least one of the patient rank calculator and the MP rank calculator and with a determined preference of a rank calculator. A control input to each of the plurality of weighting blocks controls a weighting value applied by the plurality of weighting blocks to each of the associated determined preferences. A modifier modifies the patient ranking output of the patient rank calculator with the output of the MP rank calculator to provide as an output in response to the query from the requesting patient a resultant ranking list for each of the selected at least a portion of the available MPs.
Anal abscess-fistula disease is of common occurrence and has a significant impact on the quality of life of affected individuals. The clinical course of abscess-fistula disease as well as its treatment modalities may affect anal continence. Anal fistula plug surgery is an Health Canada and FDA approved surgical treatment that has demonstrated promising results in terms of fistula healing and minimal patients' burden. The present cohort study prospectively investigates the results of anal fistula plug surgery performed in teaching hospitals affiliated to the University of Toronto. In particular, this study focus on the impact of anal fistula plug surgery on health-related quality of life, and its 2 major determinants anal continence and fistula healing. Fifty patients will be included and followed up at 6 weeks and 6 months after surgery in the clinic of participating surgeons. Quality of life and anal continence will be measured with the validated Short Form-36 Health Survey (SF-36 v2) and Fecal Incontinence Score Index (FISI) questionnaires, respectively. It is expected that the present study will provide objective information on the results and generalizability of anal fistula surgery, as well as on its impact on health-related quality of life and anal continence.
Scabies is a contagious skin disease caused by infection of mites (or scabies mites, ticks). Sarcoptic mite parasitizes the outermost layer of stratum corneum in skin, resulting in skin lesions of a patient. The scabies is winter-prone, lasts for a short time or a long time, even for several months. At present, the treatment of scabies is mainly by applying stimulant and slightly toxic drugs such as sulfur ointment, salicylic acid, 10% crotamiton cream, permethrin cream, 10%-25% benzyl benzoate lotion or cream, even lindane cream and the like to an infected part, the curative effects of these treatment methods are unsatisfactory, and the scabies is liable to reoccur. In particular, the lindane cream generates corresponding side effects after being absorbed by the skin, particularly a side effect on the central nervous system, and the side effects on pediatric patients younger than 3 years are more severe. The invention provides a traditional Chinese medicine composition for treating scabies, as well as drug proportioning and a preparation method thereof. After years of clinical application, the curative effect is reliable, the side effects are less, the application is safe and convenient and the patient compliance is good.